The ACEP24 event was a tremendous success! We want to extend our gratitude to everyone who visited our booth and participated in our Expert Theater discussion. The engagement of current and future emergency medicine leaders was truly inspiring. Our distinguished panelists shared their experiences with LIAISON® MeMed BV® to a packed room. If you missed the event, a recording will be available on the ACEP website for attendees to view. We are already looking forward to exhibiting again next year! #acep24 #diagnosticstewardship #emergencymedicine #outpaceinfection
Chi siamo
DiaSorin is an Italian multinational group, one of the leading hi-tech players in the in vitro diagnostics market and, in particular, in the immunodiagnostics and molecular diagnostics segments, with over 50 years of experience. Our Group, owned by DiaSorin S.p.A., consists of 24 Companies, 5 foreign branches, offices on the 5 Continents and 6 manufacturing facilities located in Italy, Germany, UK, USA and South Africa. We are present in more than 60 countries with our direct sales network, supported by an international network of over 100 independent distributors. We develop, manufacture and market a vast and innovative line of tests for the diagnosis of infectious diseases or hormonal disorders, specifically designed for hospital and private testing laboratories, with an offer embracing different clinical areas. With more than 2000 employees all over the world, and over 210 researchers, we focus our business on improving the health and quality of people’s lives, through high-quality diagnostic products. We count on everyone’s uniqueness, with their skill and talent sets, and it’s considered a fundamental element for the creation of a working environment of excellence, able to adapt to the needs of a constantly evolving market.
- Sito Web
-
http://www.diasorin.com/
Link esterno per DiaSorin
- Settore
- Ricerca biotecnologica
- Dimensioni dell’azienda
- 1001 - 5000 dipendenti
- Sede principale
- Saluggia, VC
- Tipo
- Società privata non quotata
- Settori di competenza
- Healthcare, Biotechnology, In Vitro Diagnostic, Immunoassay, Molecular Diagnostic, Blood tests, GI Stool Testing, Vitamin D, Prenatal screening, Infectious Diseases e Life Science
Località
-
Principale
Ottieni indicazioni
Via Crescentino
Saluggia, VC 13040, IT
-
Ottieni indicazioni
11331 Valley View St
Cypress, California, California 90630-4717, US
-
Ottieni indicazioni
1951 Northwestern Avenue PO BOX 285
Stillwater, Minnesota 55082 - 0285, US
-
Ottieni indicazioni
12212 Technology Blvd
Austin, Texas 78727, US
Dipendenti presso DiaSorin
-
Riccardo Fava
Corporate VP @ Diasorin | Corporate Communications, ESG & Investor Relations
-
Jesse Nergard
Innovator in Global Talent Acquisition: Pioneering the Future of the Biotech Workforce 🌌
-
Michael Howachyn
-
Rodrigo Pellicciari
Global Sales & Commercial Operations Executive
Aggiornamenti
-
DiaSorin ha diffuso questo post
📌 The educational and clinical Global #TB Summit 2024 is almost here! Haven't registered yet? Secure your spot at the event that's shaping the future of TB management! 👉 https://lnkd.in/ej4x8kRx ✅ With the latest #tuberculosis (TB) research, over 35 expert talks, thousands of attendees and inspiring TB stories, it's the event you can’t miss. Here are the top 3 reasons to join us.
-
You're invited to attend an informative session at #SCASM2024 on October 4th from 7:45 a.m. - 8:45 a.m. at the Hyatt Regency in room Ocean Beach 1! In our session titled “New Molecular IVDs from Diasorin - Customizable Syndromic Testing with LIAISON PLEX® & Testing Patients for C. auris Colonization with Simplexa® Direct,” attendees will hear Dr. Sukantha Chandrasekaran and Dr. Michelle Tabb discuss the significant public health threat posed by C. auris, and introduce new specialized molecular testing. Come by Booth # 109 and explore the latest in targeted and syndromic molecular testing solutions. We look forward to connecting with you! Learn more about our molecular offerings here - https://hubs.li/Q02RJlDd0 #Candidaauris #LIAISONPLEX
-
-
Did you know that an average of 1.7 million Americans are diagnosed with sepsis annually? Unfortunately, an estimated 350,000 of those cases prove to be fatal each year. Fortunately, sepsis is a preventable condition. Remember to wash your hands often, stay updated on vaccinations, and keep any wounds covered until they heal completely. Together, we can raise awareness, engage in good medical hygiene, and save lives. Learn more about sepsis with the CDC: For patients: https://hubs.li/Q02Rw_FF0 For healthcare providers: https://hubs.li/Q02Rw_GC0 #SepsisAwarenessMonth #Sepsis #SAM2024 #SepsisEducation
-
-
We are building on our legacy blood culture portfolio with the submission of the LIAISON PLEX® Gram-Negative Blood Culture Assay on the sample-to-answer LIAISON PLEX® System. Gram-negative bacteremia can lead to sepsis and occurs in approximately 30% of positive blood cultures. Optimized treatment is crucial for saving patients’ lives, and assays built with our proprietary NanoGrid technology have been at the forefront of helping clinicians make critical therapeutic decisions in hours, not days.
Following the clearance in March 2024 of the LIAISON PLEX® Respiratory Flex Assay, and in June 2024 of the LIAISON PLEX® Yeast Blood Culture Assay, Diasorin today announced it has submitted a 510(k) premarket notification to the FDA for the LIAISON PLEX ® Gram-Negative Blood Culture Assay, the second of the three molecular multiplexing panels for Blood Culture identification on the LIAISON PLEX®. “We firmly believe that LIAISON PLEX® provides unique flexibility by enabling clinicians to select the most appropriate blood panel for their patients. This ensures that clinical laboratories can generate reliable results more quickly and cost-effectively,” said Angelo Rago, President of Luminex. Read more: https://lnkd.in/dRwEu7FZ
-
-
𝗢𝗿𝗶𝗲𝗻𝘁𝗶𝗲𝗿𝘂𝗻𝗴 𝗶𝗺 𝗣𝗮𝗿𝗮𝗴𝗿𝗮𝗳𝗲𝗻𝗱𝘀𝗰𝗵𝘂𝗻𝗴𝗲𝗹 𝗱𝗲𝗿 𝗜𝗩𝗗𝗥-𝗩𝗲𝗿𝗼𝗿𝗱𝗻𝘂𝗻𝗴 Das ursprüngliche Ziel der EU-Verordnung über In-vitro-Diagnostika (IVDR) war es, die Sicherheit und Innovation in der Diagnostik zu erhöhen. Doch die Behörden erreichten leider eher das Gegenteil: Die komplexen Vorgaben führten bei vielen Verantwortlichen in der Branche zu starker Verunsicherung. Aus diesem Grund luden wir Prof. Dr. Holger F. Rabenau von der Goethe-Universität Frankfurt am Main ein, der den Teilnehmenden des Diasorin Symposiums 2024 mehr Durchblick im Dickicht der Paragrafen verschaffte. In der Aufzeichnung seines detailreichen Vortrags erfahren auch Sie mehr über: - die umfangreichen Anforderungen der IVDR - die Auswirkungen der Verordnung auf die Entwicklung von Labortests - Strategien für eine IVDR-konforme Validierung - die Umsetzung der IVDR mit praktischen Tipps und Vorlagen für Ihr Labor Sind Sie interessiert? Dann rufen Sie hier kostenlos das 35-minütige Vortragsvideo ab: https://lnkd.in/dRetRj4U #IVDR #EUVerordnung #Diagnostik #Medizinprodukte #Labortests #Innovation #Diasorinsymposium
-
-
We’d like to thank everyone who visited our booth and attended our webinars at Labroots Microbiology Virtual Week! We appreciate you taking the time to explore our latest offerings and learn more about our highly flexible testing solutions, including the next-generation LIAISON PLEX® System, the LIAISON PLEX® Respiratory Flex Assay, and the Simplexa® C. auris Direct kit. Did you miss our webinars? Access all the content you missed, now available to view on-demand on the Labroots website: https://hubs.li/Q02PNrzC0 1. Customizing Syndromic Respiratory Panels: Maximizing Patient Care through Flexible Testing Strategies 2. The Fungus Among Us - Detecting Candida auris Colonization and Yeast Bloodstream Infections
-
-
Join Diasorin in recognizing Fungal Disease Awareness Week (FDAW). As fungal infections, including C. auris infection, continue to rise around the world, this week provides a valuable opportunity to keep up-to-date on fungal disease awareness and support testing efforts worldwide. When it comes to preventing the spread of life-threatening fungal infections, accessible and actionable detection is key. Learn how effective C. auris detection supports diagnostic stewardship in our recent Labroots webinar. Visit the Labroots Microbiology Virtual Event to watch "The Fungus Among Us - Detecting Candida auris Colonization and Yeast Bloodstream Infections" webinar on-demand. https://hubs.li/Q02Qw8DF0 #FungalWeek24 #Awareness #DiagnosticStewardship
-
-
Drumroll, please! 🎉 We're excited to announce the achievement of our 7000th LIAISON® XL system! This remarkable milestone is a testament to our commitment to empowering clinical laboratories and healthcare providers. The LIAISON® XL is more than just a piece of equipment; it's a partner in patient care. By automating complex tests and delivering fast, reliable results, it helps HCPs make informed decisions and improve patient outcomes. Want to learn more about how the LIAISON® XL can transform your laboratory? Let's connect! https://lnkd.in/dus5jhBz #LIAISONXL #7000milestone #laboratoryexcellence #healthcare #patientcentric
-
-
Diasorin is sponsoring an Expert Theater during ACEP24. This is an exciting opportunity to hear from a panel of Emergency Medicine experts on the difficulties discriminating between bacterial and viral etiology in acute infection or suspected sepsis. Hear from the clinical perspective on the importance of rapid differentiation between bacterial and viral infections in patient care. Speakers: David M. Engman, MD, PhD Chairman of Pathology Emeritus - Cedars Sinai Medical Center Sam Torbati, MD Chairman of Emergency Medicine - Cedars Sinai Medical Center Mark E. Cichon, DO Chairperson Emeritus of Emergency Medicine - Loyola University Medical Center David B. Hale, MD, PhD Director of Emergency Medicine/Associate Chief Medical Officer - ThedaCare New London Hospital #acep24 #diagnosticstewardship #emergencymedicine #outpaceinfection
-